Claudio Micheletto

List of Publications by Year
in descending order

78	1,251	393982	433756
papers	citations	19 h-index	31 g-index

81	81	81	1859
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Future Perspectives of Revaluating Mild COPD. Respiration, 2022, 101, 688-696.	1.2	4
2	Severe asthma in adults does not significantly affect the outcome of COVIDâ€19 disease: Results from the Italian Severe Asthma Registry. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 902-905.	2.7	37
3	COVIDâ€19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 871-874.	2.7	33
4	Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1386-1388.	2.0	21
5	Severe asthma management in the era of biologics: insights of the Italian Registry on Severe Asthma (IRSA). European Annals of Allergy and Clinical Immunology, 2021, 53, 103.	0.4	3
6	CT radiomic models to distinguish COVID-19 pneumonia from other interstitial pneumonias. Radiologia Medica, 2021, 126, 1037-1043.	4.7	18
7	The Burden of Short-Acting Î²2-Agonist Use in Asthma: Is There an Italian Case? An Update from SABINA Program. Advances in Therapy, 2021, 38, 3816-3830.	1.3	14
8	Overcoming Barriers to the Effective Management of Severe Asthma in Italy. Journal of Asthma and Allergy, 2021, Volume 14, 481-491.	1.5	2
9	How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center. Frontiers in Oncology, 2021, 11, 669786.	1.3	8
10	Long-Term Patient-Centred Follow-up in a Prospective Cohort of Patients with COVID-19. Infectious Diseases and Therapy, 2021, 10, 1579-1590.	1.8	14
11	Exercise prehabilitation in lung cancer: Getting stronger to recover faster. European Journal of Surgical Oncology, 2021, 47, 1847-1855.	0.5	16
12	Vitamin D and disease severity in coronavirus disease 19 (COVID-19). Reumatismo, 2021, 72, 189-196.	0.4	12
13	ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments. World Allergy Organization Journal, 2021, 14, 100592.	1.6	17
14	CT-based radiomics as a tool to recognize COVID-19 positive patients. Physica Medica, 2021, 92, S46.	0.4	2
15	Prevalence of asymptomatic SARS-CoV-2-positive individuals in the general population of northern Italy and evaluation of a diagnostic serological ELISA test: a cross-sectional study protocol. BMJ Open, 2020, 10, e040036.	0.8	4
16	Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO). Frontiers in Cardiovascular Medicine, 2020, 7, 585866.	1.1	63
17	Asthmatic patients in COVID-19 outbreak: Few cases despite many cases. Journal of Allergy and Clinical Immunology, 2020, 146, 541-542.	1.5	40
18	Pneumonic versus Nonpneumonic Exacerbations of Chronic Obstructive Pulmonary Disease. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 817-829.	0.8	8

#	Article	IF	Citations
19	Relevance of TH2 Markers in the Assessment and Therapeutic Management of Severe Allergic Asthma: A Real-Life Perspective. Journal of Investigational Allergology and Clinical Immunology, 2020, 30, 35-41.	0.6	15
20	Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis. Pulmonary Pharmacology and Therapeutics, 2019, 59, 101855.	1.1	16
21	Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response. Expert Review of Respiratory Medicine, 2019, 13, 1205-1212.	1.0	25
22	Clinical and Functional Characteristics of COPD Patients Across GOLD Classifications: Results of a Multicenter Observational Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2019, 16, 215-226.	0.7	16
23	A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management . International Journal of COPD, 2019, Volume 14, 2185-2193.	0.9	3
24	Severe Asthma in adolescents and adults: a National, multicenter registry in real life. European Annals of Allergy and Clinical Immunology, 2018, 50, 196.	0.4	3
25	Late Breaking Abstract - Impact of ICS/LABA and LABA/LAMA FDCs on lung function and exacerbation of COPD: a network meta-analysis. , 2018, , .		0
26	Role of different spirometric reference equations for lung volumes assessment. , 2018, , .		0
27	Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36Âmonths. Clinical and Translational Allergy, 2017, 7, 6.	1.4	55
28	Inhalation errors due to device switch in patients with chronic obstructive pulmonary disease and asthma: critical health and economic issues. International Journal of COPD, 2016, 11, 597.	0.9	44
29	Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience. BMC Pulmonary Medicine, 2016, 16, 128.	0.8	38
30	Near fatal asthma: treatment and prevention. European Annals of Allergy and Clinical Immunology, 2016, 48, 116-22.	0.4	8
31	Small airway dysfunction and bronchial asthma control : the state of the art. Asthma Research and Practice, 2015, 1, 13.	1.2	29
32	Potential Economic Impact Of Inhalation Errors Due To Device Switch In Patients With Chronic Obstructive Pulmonary Disease And Asthma. Value in Health, 2015, 18, A370.	0.1	0
33	Outcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the Italian perspective of the PATHOS study. International Journal of COPD, 2014, 9, 569.	0.9	8
34	Health and social impacts of COPD and the problem of under-diagnosis. Multidisciplinary Respiratory Medicine, 2014, 9, 63.	0.6	10
35	Omalizumab management beyond clinical trials: The added value of a network model. Pulmonary Pharmacology and Therapeutics, 2014, 29, 74-79.	1.1	19
36	Subglotic Malt-Lymphoma of the Larynx: An Unusual Presentation of Chronic Cough. International Journal of Immunopathology and Pharmacology, 2014, 27, 461-465.	1.0	10

#	Article	IF	Citations
37	Prevalence of tracheobronchomalacia and excessive dynamic airway collapse in bronchial asthma of different severity. Multidisciplinary Respiratory Medicine, 2013, 8, 32.	0.6	31
38	Lung metastasis from TTF-1 positive sigmoid adenocarcinoma. pitfalls and management. Pathologica, 2013, 105, 69-72.	1.3	9
39	Omalizumab Modulates Bronchial Reticular Basement Membrane Thickness and Eosinophil Infiltration in Severe Persistent Allergic Asthma Patients. International Journal of Immunopathology and Pharmacology, 2012, 25, 475-484.	1.0	106
40	Effects of tiotropium and formoterol on quiet breathing pattern assessed by optoelectronic plethysmography in COPD patients: a pilot study. Therapeutic Advances in Respiratory Disease, 2012, 6, 97-105.	1.0	4
41	Clinical Outcomes. , 2012, , 195-210.		0
42	Pattern of airway inflammation and remodelling in mild persistent atopic asthma and in mild persistent asthma related to gastroesophageal reflux. European Annals of Allergy and Clinical Immunology, 2012, 44, 236-42.	0.4	6
43	Changes in Total IgE Plasma Concentration Measured at the Third Month during Anti-IgE Treatment Predict Future Exacerbation Rates in Difficult-to-Treat Atopic Asthma: A Pilot Study. Journal of Asthma, 2011, 48, 437-441.	0.9	14
44	Changes of clinical outcomes and health care resources in moderate and in severe COPD treated uniquely with tiotropium 18Âmcg od for twenty-four months. Pulmonary Pharmacology and Therapeutics, 2011, 24, 373-376.	1.1	5
45	The impact of LABA+ICS fixed combinations on morbidity and economic burden of COPD in Italy: a six-year observational study. Therapeutic Advances in Respiratory Disease, 2011, 5, 83-90.	1.0	2
46	Erdosteine affects eicosanoid production in COPD. International Journal of Clinical Pharmacology and Therapeutics, 2011, 49, 41-45.	0.3	17
47	Reference urinary LTE4 levels in normal individuals: a pilot study. European Annals of Allergy and Clinical Immunology, 2011, 43, 22-8.	0.4	5
48	Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. European Annals of Allergy and Clinical Immunology, 2011, 43, 45-53.	0.4	28
49	Erdosteine But Not Placebo Reduces The Exercise-induced Oxidative Stress In Severe COPD. , 2010, , .		0
50	Sensitivity And Specificity Of A Nucleic Acid Amplification Test (AMT-BK) For Tuberculosis Detection. , 2010, , .		0
51	The prevalence of nasal polyps and the corresponding urinary LTE4 levels in severe compared to mild and moderate asthma. European Annals of Allergy and Clinical Immunology, 2010, 42, 120-4.	0.4	9
52	A MCh Test Pre-post Esophageal Acidification in Detecting GER-related Asthma. Journal of Asthma, 2009, 46, 351-355.	0.9	7
53	PRS28 ADD-ON OMALIZUMAB IN PERSISTENT DIFFICULT-TO-TREAT ASTHMA: A 12-MONTH STUDY ON CLINICAL, ECONOMIC OUTCOMES AND RELATED COST/UTILITY. Value in Health, 2009, 12, A303-A304.	0.1	0
54	Tobramycin Nebulizer Solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial Inflammation. Advances in Therapy, 2008, 25, 1019-1030.	1.3	56

#	Article	IF	Citations
55	Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: A controlled study in current smokers with mild COPD. Pulmonary Pharmacology and Therapeutics, 2008, 21, 304-308.	1.1	42
56	Erdosteine enhances airway response to salbutamol in patients with mild-to-moderate COPD. Therapeutic Advances in Respiratory Disease, 2008, 2, 271-277.	1.0	13
57	BASEMENT MEMBRANE THICKNESS, EOSINOPHILIC INFLAMMATION AND URINARY LTE4 IN PATIENTS WITH NASAL POLYPS WITH OR WITHOUT BRONCHIAL ASTHMA. Chest, 2007, 132, 507A.	0.4	0
58	Cost analysis of GER-induced asthma: A controlled study vs. atopic asthma of comparable severity. Respiratory Medicine, 2007, 101, 1814-1820.	1.3	7
59	Costs of asthma in Italy: Results of the SIRIO (Social Impact of Respiratory Integrated Outcomes) study. Respiratory Medicine, 2007, 101, 2511-2519.	1.3	23
60	Urinary LTE4 is higher after nasal provocation test with L-ASA in bronchial than in only nasal responders. European Annals of Allergy and Clinical Immunology, 2007, 39, 162-6.	0.4	3
61	Changes in urinary LTE4 and nasal functions following nasal provocation test with ASA in ASA-tolerant and -intolerant asthmatics. Respiratory Medicine, 2006, 100, 2144-2150.	1.3	19
62	Complicazioni nei pazienti in ossigenoterapia domiciliare a lungo termine. , 2006, , 113-122.		0
63	Nasal and bronchial tolerability of Rofecoxib in patients with aspirin induced asthma. European Annals of Allergy and Clinical Immunology, 2006, 38, 10-4.	0.4	18
64	Aspirin induced asthma (AIA) with nasal polyps has the highest basal LTE4 excretion: a study vs AIA without polyps, mild topic asthma, and normal controls. European Annals of Allergy and Clinical Immunology, 2006, 38, 20-3.	0.4	18
65	The therapeutic effects of inhaled long-acting beta2-adrenergics (LABA) and corticosteroids (ICS) are not affected by their inhalation sequence in moderate/persistent asthma. European Annals of Allergy and Clinical Immunology, 2006, 38, 153-7.	0.4	0
66	EOSINOPHILIC INFLAMMATION AND BASEMENT MEMBRANE THICKNESS (BMT) IN ATOPIC AND IN GER-RELATED ASTHMA. Chest, 2005, 128, 147S.	0.4	0
67	A Two-Stage Logistic Model Based on the Measurement of Pro-Inflammatory Cytokines in Bronchial Secretions for Assessing Bacterial, Viral, and Non-Infectious Origin of COPD Exacerbations. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2005, 2, 7-16.	0.7	25
68	Effects of HFA- and CFC-beclomethasone dipropionate on the bronchial response to methacholine (MCh) in mild asthma. Respiratory Medicine, 2005, 99, 850-855.	1.3	10
69	Montelukast 10 mg improves nasal function and nasal response to aspirin in ASA-sensitive asthmatics: a controlled study vs placebo. Allergy: European Journal of Allergy and Clinical Immunology, 2004, 59, 289-294.	2.7	37
70	Additive Effects of Montelukast on Bronchial Hyperresponsiveness to MCh and LTE4 Urine Levels in Mild-persistent Atopic Asthmatics Assuming ICS. Chest, 2004, 126, 814S.	0.4	4
71	Assessment of inhaled BDP-dose dependency of exhaled nitric oxide and local and serum eosinophilic markers in steroids-naive nonatopic asthmatics. Allergy: European Journal of Allergy and Clinical Immunology, 2003, 58, 1018-1022.	2.7	12
72	Salmeterol & Fluticasone 50 Î¼g/250 Î¼g bid in combination provides a better long-term control than salmeterol 50 Î¼g bid alone and placebo in COPD patients already treated with theophylline. Pulmonary Pharmacology and Therapeutics, 2003, 16, 241-246.	1.1	58

#	Article	IF	Citations
73	Pharmacokinetics of the Effect of Nebivolol 5mg on Airway Patency in Patients with Mild to Moderate Bronchial Asthma and Arterial Hypertension. Clinical Drug Investigation, 2002, 22, 197-204.	1.1	8
74	Evidence of Adequacy of the Performance of the Pulvinalâ„¢ by Measuring Through-Device Peak Inspiratory Flow Rate in Severe Airways Obstruction in Adults and Children. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2001, 14, 343-349.	1.2	4
75	Prevalence of gastro-oesophageal reflux in asthmatics: an Italian study. Italian Journal of Gastroenterology and Hepatology, 1999, 31, 371-5.	0.5	11
76	Effect of inhaled beclomethasone dipropionate and budesonide dry powder on pulmonary function and serum eosinophil cationic protein in adult asthmatics. Journal of Investigational Allergology and Clinical Immunology, 1999, 9, 241-7.	0.6	4
77	Hypo-osmolar aerosol induces hyperventilation in chronic non-asthmatic rhinitics. Respiratory Medicine, 1998, 92, 9-13.	1.3	1
78	Serum eosinophil cationic protein and bronchial hyperresponsiveness to hypoosmolar challenge in naive atopic asthmatics. Journal of Investigational Allergology and Clinical Immunology, 1998, 8, 294-9.	0.6	2